Payment overview · 2025
General Payments
$1,074.29
47 reported records · 17 companies
Healthcare provider profile · identity verified
Yazan Khatib, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · JACKSONVILLE, FL · NPI 1588653257
Verified facts
What the public records show
CMS Open Payments records show Yazan Khatib, MD received $1,074.29 in general payments during 2025 across 47 reported records.
Bard Peripheral Vascular, Inc. accounted for 23.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Jardiance by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Eliquis by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Eliquis by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $248.28 | 23.1% | 17 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $161.48 | 15.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $144.90 | 13.5% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $123.26 | 11.5% | 6 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$84.83 | 7.9% | 5 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $57.14 | 5.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $52.44 | 4.9% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.20 | 2.8% | 1 | 2025 |
| Terumo Medical Corporation | Unresolved — no canonical attribution shown | $24.97 | 2.3% | 1 | 2025 |
| CORDIS US CORP. | Unresolved — no canonical attribution shown | $24.74 | 2.3% | 1 | 2025 |
| InspireMD Ltd | Unresolved — no canonical attribution shown | $21.41 | 2.0% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $19.54 | 1.8% | 1 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $18.85 | 1.8% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $16.88 | 1.6% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.15 | 1.5% | 1 | 2025 |
| Innovation Technologies Inc | Unresolved — no canonical attribution shown | $14.73 | 1.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.49 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,074.29 | 47 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Venovo Normalized: venovo |
Device | Bard Peripheral Vascular, Inc. | $178.46 | 12 | 2025 |
Source payment records
|
|||||
| LIMFLOW SYSTEM Normalized: limflow system |
Device | Stryker Corporation | $161.48 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $123.26 | 6 | 2025 |
Source payment records
|
|||||
| XACT Normalized: xact |
Device | Abbott Laboratories | $119.66 | 1 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $57.14 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | Celgene Corporation, PFIZER INC. | $46.12 | 2 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $41.97 | 2 | 2025 |
Source payment records
|
|||||
| TURBOHAWK Normalized: turbohawk |
Device | Medtronic, Inc. | $39.14 | 2 | 2025 |
Source payment records
|
|||||
| RotarexS 6 F x 135 cm Normalized: rotarexs 6 f x 135 cm |
Device | Bard Peripheral Vascular, Inc. | $37.26 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $30.20 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $25.17 | 1 | 2025 |
Source payment records
|
|||||
| TR BAND Normalized: tr band |
Device | Terumo Medical Corporation | $24.97 | 1 | 2025 |
Source payment records
|
|||||
| MYNX CONTROL VENOUS Normalized: mynx control venous |
Device | CORDIS US CORP. | $24.74 | 1 | 2025 |
Source payment records
|
|||||
| WavelinQ Normalized: wavelinq |
Device | Bard Peripheral Vascular, Inc. | $23.90 | 2 | 2025 |
Source payment records
|
|||||
| CGuard Prime Carotid Stent System Normalized: cguard prime carotid stent system |
Device | InspireMD Ltd | $21.41 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $19.54 | 1 | 2025 |
Source payment records
|
|||||
| DIAMONDBACK PERIPHERAL Normalized: diamondback peripheral |
Device | Abbott Laboratories | $18.24 | 2 | 2025 |
Source payment records
|
|||||
| EVKEEZA Normalized: evkeeza |
Biological | Regeneron Healthcare Solutions, Inc. | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| TELESCOPE Normalized: telescope |
Device | Medtronic, Inc. | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| ABRE Normalized: abre |
Device | Medtronic, Inc. | $15.15 | 1 | 2025 |
Source payment records
|
|||||
| IRRISEPT Normalized: irrisept |
Device | Innovation Technologies Inc | $14.73 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.49 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.49 | 1 | 2025 |
Source payment records
|
|||||
| IN.PACT ADMIRAL Normalized: in pact admiral |
Device | Medtronic, Inc. | $14.19 | 1 | 2025 |
Source payment records
|
|||||
| Denali Vena Cava Filter Normalized: denali vena cava filter |
Device | Bard Peripheral Vascular, Inc. | $8.66 | 1 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $7.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 167 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 60 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 151 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
151 | 44 |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
167 | 54 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
167 | 54 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
60 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
167 | 54 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 664 | 246 |
| Clopidogrel | Clopidogrel Bisulfate | 646 | 239 |
| Metoprolol Succinate | Metoprolol Succinate | 423 | 174 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 371 | 125 |
| Spironolactone | Spironolactone | 368 | 134 |
| Amlodipine Besylate | Amlodipine Besylate | 313 | 117 |
| Losartan Potassium | Losartan Potassium | 267 | 104 |
| Furosemide | Furosemide | 218 | 79 |
| Carvedilol | Carvedilol | 190 | 77 |
| Lisinopril | Lisinopril | 186 | 74 |
| Eliquis | Apixaban | 167 | 54 |
| Hydralazine Hcl | Hydralazine Hcl | 155 | 52 |
| Jardiance | Empagliflozin | 151 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 144 | 53 |
| Ezetimibe | Ezetimibe | 114 | 42 |
| Xarelto | Rivaroxaban | 112 | 34 |
| Cilostazol | Cilostazol | 102 | 39 |
| Repatha Sureclick | Evolocumab | 72 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 68 | 31 |
| Entresto | Sacubitril/Valsartan | 60 | 18 |
| Farxiga | Dapagliflozin Propanediol | 57 | 21 |
| Varenicline Tartrate | Varenicline Tartrate | 55 | 25 |
| Amiodarone Hcl | Amiodarone Hcl | 53 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 51 | 21 |
| Atenolol | Atenolol | 45 | 15 |
| Repatha Syringe | Evolocumab | 42 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | 13 |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | 12 |
| Torsemide | Torsemide | 32 | suppressed |
| Potassium Chloride | Potassium Chloride | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | 11 |
| Nitroglycerin | Nitroglycerin | 21 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | 17 |
| Prasugrel Hcl | Prasugrel Hcl | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Gabapentin | Gabapentin | 15 | suppressed |
| Omeprazole | Omeprazole | 15 | suppressed |
| Ozempic | Semaglutide | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 14 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Metformin Hcl | Metformin Hcl | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,074.29 · 47 records | Bard Peripheral Vascular, Inc. | ABRE, AREXVY, Barostim Neo System, CAMZYOS, CGuard Prime Carotid Stent System, DIAMONDBACK PERIPHERAL, Denali Vena Cava Filter, ELIQUIS, ENTRESTO, ESPRIT, EVKEEZA, IN.PACT ADMIRAL, IRRISEPT, JARDIANCE, LEQVIO, LIMFLOW SYSTEM, MYNX CONTROL VENOUS, RotarexS 6 F x 135 cm, SHINGRIX, Senza, TELESCOPE, TR BAND, TURBOHAWK, VYNDAQEL, Venovo, WavelinQ, XACT | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error